Lipid‐based nucleic acid therapeutics with in vivo efficacy-Reference-Cited by-同舟云学术

Lipid‐based nucleic acid therapeutics with in vivo efficacy

Published:2022-09-30 Issue:2 Volume:15 Page:
ISSN:1939-5116
Container-title:WIREs Nanomedicine and Nanobiotechnology
language:en
Short-container-title:WIREs Nanomed Nanobiotechnol

Author:

Sufian Md. Abu¹,Ilies Marc A.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences and Moulder Center for Drug Discovery Research, School of Pharmacy Temple University Philadelphia Pennsylvania USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/wnan.1856

Reference352 articles.

1. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

2. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

3. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity

4. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer

5. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Optimization of a Bromothymol Blue-Based PLA2 Assay Involving POPC-Based Self-Assemblies;International Journal of Molecular Sciences;2024-09-01

2. The optimization strategies of LNP-mRNA formulations: Development and challenges for further application;Journal of Drug Delivery Science and Technology;2024-05

3. Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities;International Journal of Biological Macromolecules;2024-05

4. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy;Journal of Translational Medicine;2023-10-04

5. Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy;Frontiers in Chemistry;2023-09-28